CDRH Staffers To Obama: Housecleaning Urgently Needed At Device Center
This article was originally published in The Pink Sheet Daily
Whistleblowers charge management with “coercing and intimidating” staff, indict Office of Device Evaluation director and call for ODE reorganization – from the bottom up.
You may also be interested in...
ReGen Biologics plans a February U.S. launch of its Menaflex collagen knee cartilage repair product at the 2009 American Academy of Orthopedic Surgeons meeting in Las Vegas now that FDA has signed off on the product after several years of resistance
FDA's device center has until Dec. 1 to respond to a Congressional inquiry into allegations of wrongdoing in its pre-market review process
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.